These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 17459751

  • 1. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
    Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC.
    Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
    [Abstract] [Full Text] [Related]

  • 2. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A.
    Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
    [Abstract] [Full Text] [Related]

  • 3. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C, Muro-Tudelilla JM, Cancho-Candela R, Gutiérrez-Solana LG, Pintos-Morell G, Martí-Herrero M, Munguira-Aguado P, Galán-Gómez E.
    Eur J Med Genet; 2010 Mar; 53(6):371-7. PubMed ID: 20709629
    [Abstract] [Full Text] [Related]

  • 4. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA, Kimura A.
    Drug Des Devel Ther; 2017 Mar; 11():2467-2480. PubMed ID: 28860717
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
    Sohn YB, Cho SY, Park SW, Kim SJ, Ko AR, Kwon EK, Han SJ, Jin DK.
    Orphanet J Rare Dis; 2013 Mar 18; 8():42. PubMed ID: 23497636
    [Abstract] [Full Text] [Related]

  • 10. Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome).
    Papadia F, Lozupone MS, Gaeta A, Capodiferro D, Lacalendola G.
    Eur Rev Med Pharmacol Sci; 2011 Mar 18; 15(3):253-8. PubMed ID: 21528770
    [Abstract] [Full Text] [Related]

  • 11. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE.
    Acta Paediatr; 2008 Apr 18; 97(457):76-8. PubMed ID: 18339193
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N, Kida S, Kinoshita M, Morimoto H, Shibasaki T, Tachibana K, Yamamoto R.
    Mol Genet Metab; 2018 Sep 18; 125(1-2):53-58. PubMed ID: 30064964
    [Abstract] [Full Text] [Related]

  • 13. Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome.
    Galán-Gómez E, Guerrero-Rico A, Cáceres-Marzal C, Zambrano-Castaño M, Moreno-Tejero ML, Grande-Tejada AM, Fernández-Hernández S, Vaquerizo-Madrid J, Cardesa-García JJ.
    Eur J Med Genet; 2008 Sep 18; 51(3):268-71. PubMed ID: 18396123
    [Abstract] [Full Text] [Related]

  • 14. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T, Shimizu H, Fukuda T, Kawagoe S, Matsumoto J, Shimada Y, Kobayashi H, Ida H, Ohashi T, Morimoto H, Hirato T, Nishino K, Eto Y.
    Mol Genet Metab; 2012 Sep 18; 107(1-2):122-8. PubMed ID: 22704483
    [Abstract] [Full Text] [Related]

  • 15. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A, Watanabe H, Nakajima T, Inazu T.
    Clin Chim Acta; 2013 Aug 23; 423():66-8. PubMed ID: 23726270
    [Abstract] [Full Text] [Related]

  • 16. Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
    Maccari F, Rigon L, Mantovani V, Galeotti F, Salvalaio M, D'Avanzo F, Zanetti A, Capitani F, Gabrielli O, Tomanin R, Volpi N.
    J Mol Med (Berl); 2022 Aug 23; 100(8):1169-1179. PubMed ID: 35816218
    [Abstract] [Full Text] [Related]

  • 17. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report.
    Kim S, Whitley CB, Jarnes Utz JR.
    Mol Genet Metab; 2017 Sep 23; 122(1-2):92-99. PubMed ID: 28610913
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB, Cho SY, Lee J, Kwun Y, Huh R, Jin DK.
    Mol Genet Metab; 2015 Feb 23; 114(2):156-60. PubMed ID: 25219292
    [Abstract] [Full Text] [Related]

  • 19. Comparative study of idursulfase beta and idursulfase in vitro and in vivo.
    Kim C, Seo J, Chung Y, Ji HJ, Lee J, Sohn J, Lee B, Jo EC.
    J Hum Genet; 2017 Feb 23; 62(2):167-174. PubMed ID: 27829684
    [Abstract] [Full Text] [Related]

  • 20. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
    Barbier AJ, Bielefeld B, Whiteman DA, Natarajan M, Pano A, Amato DA.
    Mol Genet Metab; 2013 Nov 23; 110(3):303-10. PubMed ID: 23988379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.